info@rareimpact.euPhase 2 of the RARE IMPACT initiative aims to further gather information and propose solutions to improve patients’ access to gene and cell therapies.
Following the RARE IMPACT recommendations proposed under the Phase 1, the current work is composed of three following activity areas:
- Price and the economics of ATMPs: Enabling a stakeholder dialogue in support of patient access and innovation (Workstream 1).
- Evidence generation for ATMPs: Building consensus among stakeholders to accelerate patient access (Workstream 2).
- Processes and criteria of selection of Centres of Expertise for ATMPs (Workstream 3).
